LLS TAP to Support COVID-19 Antibody Clinical Studies
Apply by March 31, 2021
Is your company a leading biotech developing antibody therapeutics against SARS-CoV-2?
If so, please apply for this RFP by completing this initial funding request form and send it along with a non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead.
Patients with hematological malignancies are more susceptible to SARS-CoV-2 infection, suffer delayed recovery and higher mortality rate, in comparison to healthy individuals. While the rollout of vaccines will provide much needed protection for the general public, efficacious treatment options following a SARS-CoV-2 diagnosis or as (post-exposure) prophylaxis, are still very desirable for these patients.
LLS TAP can provide co-funding to support clinical trials that include blood cancer patients to study your antibody therapeutics as treatment or infection prevention. Based on to the emergence of new variants, demonstrated preclinical efficacy of a drug candidate towards the UK, SA and BZ variants will be an important consideration for funding.
TAP Accepts and Reviews Funding Requests Year Round
- Companies: click here to download the biotech accelerator initial inquiry form
- Institutions: click here to download the academic clinical initial inquiry form
Want to know more about applying, please download a presentation and a one-pager that describe how TAP works.
Send a completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead, Therapy Acceleration Program®
How did TAP benefit Forty Seven?
Listen to what the Chief Medical Officer of Forty Seven, Chris Takimoto, has to say about TAP and the value created for his company.
Recently Forty Seven was acquired by Gilead Sciences for $4.9 Billion.
How did TAP benefit Stemline Therapeutics?
Listen to what the SVP of Corporate & Business Development of Stemline, Peter McDonald, has to say about TAP and the value created for his company.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Due Diligence Process
Typically takes 3-6 months, but varies based on company responsiveness to LLS requests.
